An Eli Lilly & Co. patent describes new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes type 2, hyperglycemia and obesity.
Genetic variants in core-spliceosome components are tied to a variety of aberrant splicing-driven inherited disorders. CWF19-like protein 2 (CWF19L2) is such a key component located in the spliceosome complex in charge of maturing pre-RNA. No disease-phenotype has been established for CWF19L2.
Calidi Biotherapeutics Inc. has conducted studies in animals to determine the safety and efficacy of oncolytic virotherapy (OV) with CLD-201 (Supernova-1) to treat solid tumors.
Scientists at de Duve Institute focused on the genetic causes of vascular anomalies, more specifically on capillary malformation with dilated veins (CMDV).
Researchers from Charité University Hospital Berlin and affiliated organizations presented data from a study that linked variants in ANO4 to different types of epilepsy.
Previous studies have found that the effectiveness of vaccines can be increased with the knockdown of HBsAg using a small interfering RNA (siRNA). The efficacy of a bivalent mRNA vaccine in combination with the siRNA AD-66810, which targets the X gene expression in the hepatitis B virus (HBV) genome, was tested in a murine model of AAV/HBV by scientists from Clearb Therapeutics Inc.
Shionogi & Co. Ltd. has entered into an option agreement with Cilcare Dev SAS to acquire the exclusive license for the global development, manufacturing and commercialization of hearing loss treatment drug candidates CIL-001 and/or CIL-003.
Calidi Biotherapeutics Inc. has announced a collaboration with Siga Technologies Inc. to support the development of Calidi’s systemic and targeted Rtnova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
Chengdu Easton Biopharmaceuticals Co. Ltd. recently presented findings that highlight the potential anticancer agent D0112-005 as a potent and selective poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor with excellent antitumor efficacy and a good safety profile in vivo.